Journal of Dermatology and Clinical Research 2(2): 2013

Autori: Adele Sparavigna1, Maurizio Caserini2, Beatrice Tenconi1, Ileana De Ponti1 and Renata Palmieri2
1DermIng, Clinical Research and Bioengineering Institute, Italy
2Scientific Department, Polichem SA, Switzerland

HPCH nail lacquer is a medical device intended to relieve symptoms and signs of nail dystrophy. Its main ingredients are hydroxypropyl-chitosan (HPCH), Equisetum arvense and methylsulphonyl-methane. In order to investigate the exact role of HPCH in this medical device, the HPCH nail lacquer was compared to another nail lacquer (P-09-005) with identical composition, except for the presence of insoluble chitosan instead of HPCH. Thirty-four healthy women with onychoschizia of the fingernails were included. Both products were applied by all subjects once daily on the affected fingernails of either hand at random, for 4 weeks. The severity of nail signs was assessed using a 0-3 scale. Nail surface profilometry was assessed by morphometrical analysis of nail grooves on nail casts. Visual score of onychoschizia improved at T4 in 74% of volunteers with HPCH nail lacquer and in 52% with P-09-005 (Wilcoxon test p<0.05 between treatments). Severe onychoschizia, present in 35% of patients at baseline, improved at T4 in 80% of subjects with HPCH nail lacquer (Dunnett test p<0.05: T4 vs T0) and in 42% with P-09-005. On the morphometrical analysis a significant reduction of rugosity of the longitudinal nail grooves was noticed (Dunnett test p<0.05: T4 vs T0): 19% for HPCH nail lacquer and 16% for P-09-005 (not significant between treatments). Both products were well tolerated. In conclusion, HPCH nail lacquer proved to be effective in improving the nail structure and appearance in subjects with onychodystrophy. The presence of HPCH in the formulation was specifically effective in decreasing lamellar splitting.